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The discovery and subsequent clinical introduction of antibiotics is one of the most important
game-changers in the history of medicine [1]. These drugs have saved millions of lives from
infections that would previously have been fatal, and later, they allowed for the introduction of
surgical interventions, organ transplantation, care of premature infants, and cancer chemotherapy [2].
Nevertheless, the therapy of bacterial infections is becoming less and less straightforward due to the
emergence of multidrug resistance (MDR) in these pathogens [3]. Direct consequences of antibiotic
resistance include delays in the onset of the appropriate (effective) antimicrobial therapy, the need
to use older, more toxic antibiotics (e.g., colistin) with a disadvantageous side-effect profile, longer
hospital stays, and an increasing burden on the healthcare infrastructure; overall, a decrease in the
quality-of-life (QoL) and an increase in the mortality rate of the affected patients [4,5]. To highlight
the severity of the issue, several international declarations have been published to call governments
around the globe to take action on antimicrobial resistance [6–9].
Since the 1980s, pharmaceutical companies have slowly turned away from antimicrobial research
and towards the drug therapy of chronic non-communicable diseases [10,11]. New antimicrobials
are usually used as last-resort agents in a narrow patient population, resulting in smaller profits [12].
Additionally, drug companies are failing to keep up with the developments in global resistance levels;
development of non-susceptibility to the novel antibiotics is inevitable, shortening the period of clinical
usefulness of these drugs [13]. During the last years, a number of antibiotics have received marketing
authorization from the Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) (Table 1) [14–16].
Table 1. Antibiotics recently approved by the Food and Drug Administration (FDA) and/or European
Medicines Agency (EMA).
Active Pharmaceutical
Ingredient Trade Name Class/Comments
Doripenem Doribax
™ (US)
Finibax ™ (EU)
Carbapenem
Ceftaroline fosamil Teflaro
™ (US)
Zinforo™ (EU)
Cephalosporin
Ceftobiprole medocaril Zevtera
™(US)
Mabelio™ (EU)
Cephalosporin
Ceftolozane/tazobactam Zerbaxa ™ (US/EU)
Combination antibiotic: cephalosporin/β-lactamase
inhibitor
Ceftazidime/avibactam Avycaz™ (US/EU)
Combination antibiotic: cephalosporin/β-lactamase
inhibitor
Meropenem/vaborbactam Vabomere
™ (US)
Carbavance™ (EU)
Combination antibiotic: carbapenem/β-lactamase
inhibitor
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Table 1. Cont.
Active Pharmaceutical
Ingredient Trade Name Class/Comments
Imipenem/cilastatin/relebactam Recarbrio ™ (US/EU)
Combination antibiotic: carbapenem/renal
dehydropeptidase inhibitor/β-lactamase inhibitor
Telavancin Vibativ™ (US) Derivatives of either vancomycin or lipoglycopeptide
Dalbavancin Dalvance
™ (US)
Xydalba™ (EU)
Derivatives of either vancomycin or lipoglycopeptide
Oritavancin Orbactiv™ (US/EU) Derivatives of either vancomycin or lipoglycopeptide
Eravacycline Xerava™ (US/EU) Tetracycline derivatives
Sarecycline Seysara™ (US) Tetracycline derivatives
Omadacycline Nuzyra™ (US) Tetracycline derivatives
Bedaquiline, Sirturo™ (US/EU) Diarylquinoline (DARQ)
Tedizolid Sivextro ™ (US/EU) Oxazolidinone
Delafloxacin meglumine Baxdela™ (US) Fluoroquinolone
Plazomicin Zemdri ™ (US) Next-generation aminoglycoside (neoglycoside)
Lefamulin Xenleta™ (US) Pleuromutilin
US: Trade name in the United States; EU: trade name in the member states of the European Union.
Although the number of newly marketed antibiotics and the current state of the antimicrobial
pipeline offers hope (owing to government-funded research programs and public–private partnerships,
generating incentive for pharmaceutical companies), there are several pathogens where providing
appropriate therapy is still a major concern [10–13]. Based on their resistance levels and clinical
significance, the so-called “ESKAPE” pathogens (Table 2) receive the utmost attention when it comes to
the development of novel antimicrobials [17–21]. This was further highlighted after the World Health
Organization declared these microorganisms as priority pathogens for pharmaceutical companies [22].
Table 2. Current list of ESKAPE pathogens.
Pathogens
Enterococcus faecium
Staphylococcus aureus
(Stenotrophomonas maltophilia)
Klebsiella pneumoniae
(Clostridioides difficile)
Acinetobacter spp.
Pseudomonas aeruginosa
Enterobacter spp.
(members of Enterobacterales)
One of the main driving forces behind the development of antibacterial drug resistance
is the misuse and overuse of these drugs, both in human medicine and in agriculture [1–3].
Thus, programs and interventions aiming at optimizing the use of antimicrobial drugs (such as
implementation of policies and guidelines, drug utilization reports, point prevalence surveys, both
locally and internationally), collectively termed “antimicrobial stewardship”, have received substantial
attention [23]. Antimicrobial stewardship includes decisions like the selection of the dose and duration
of the most appropriate antimicrobial(s) for the patient with limited or no side effects, ensuring
minimal impact on local resistance levels, ensuring their availability and efficacy for the future [24].
In addition, the implementation of rapid diagnostic techniques in clinical microbiology laboratories
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(diagnostic stewardship) to aid the choice of drug therapy is another emerging facet of antimicrobial
stewardship [25]. This is also highlighted in scientific research; while in 2008, there were only n = 45
articles on this topic, in 2018, a nearly twenty-fold increase was observed (n = 804). To attain changes
clinical practice, the appropriate attitude of healthcare professionals and their continuous professional
development is of utmost importance [26,27].
Considering the importance of antibiotic resistance and its effects on the QoL of patients and
on the state of healthcare infrastructures as a whole, it is our pleasure to co-edit the Special Issue in
Antibiotics, termed “Antibiotic Resistance: From the Bench to Patients”. The Special Issue contains
excellent quality research articles and comprehensive review papers on the epidemiology of various
MDR pathogens worldwide, novel diagnostic and point-of-care (POCT) tests, interventional studies on
antimicrobial drug utilization and pharmaco-epidemiological studies. In addition, the Special Issue
welcomes reports on the knowledge, attitude, and practice of healthcare professionals (nurses, doctors,
pharmacists, etc.) and patients regarding antibiotics and antibiotic resistance.
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